Seagate-backed customised silicon device maker Easic aims to float on Nasdaq after raising $120m in venture funding.

MedImmune-backed Inotek, which is working on treatments for glaucoma, priced its IPO at $6a share and is set to secure an additional $20m in convertible debt.

Invitae, a genetic testing technology spin-out from Genomic Health, had initially raised $101.6m when it floated last week.

The agricultural biotechnology developer had raised $101m from investors including chemical producer BASF.

Poxel, which is also backed by Bpifrance, will fund clinical trials for two of its drug candidates with the proceeds.

Genomic Health-backed Invitae will offer 6.35 million shares priced at $16, raising $101.6m.

Intel-backed transplant surveillance technology company CareDx has raised $40m in its initial public offering.

The Hearst-backed social media tools developer has raised $250m to date, but could wait another two years before looking to go public.

The pharmaceutical company, which is developing treatments for retinal conditions, is set to float above its range.

The Kraft-backed biotechnology company, which is developing treatments for neuromuscular disorders, has gone public just five months after a $40m series A round.